The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say. While the Federal Trade Commission’s recent challenge to Amgen Inc.’s AMGN, acquisition of…
#amgenincs #amgn #ftc #amgen #evandavidseigerman #bmocapitalmarkets #pfizer #pfe #seagen #elilillycos
Continue reading...